In small-HIS-low tumors of MCA38-pCDH and MCA38-PD-L1, the rates of tumor growth inhibition (TGI) upon anti-PD1 therapy were 84.6% and 75.7%, respectively (Fig. 4A). This evidence concerns the gene CD274 and neoplasm.